Acessibilidade / Reportar erro

Syncope as a Phenotypic Expression of Hereditary Transthyretin Amyloidosis Val142Ile (Val122Ile)

Keywords:
Syncope; Amyloidosis, Familial/genetics; Amyloid Neuropathies, Familial; Cardiomyopathies/diagnosis; Diagnostic, Imaging/methods; Prevalence

Introduction

Transthyretin amyloidosis (ATTR) is a familial disease caused by one of more than 100 described mutations, where there is production of amyloids that are deposited in tissues.11 Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9. Phenocopies include neuropathy (autonomic and peripheral), cardiomyopathy, renal, gastrointestinal, vitreous and meningeal involvement, which vary according to the genetic mutation, ethnicity and geographical origin, even among individuals with the same mutation or within the same family.22 Ando Y, Coelho T, Berk JL, Waddington Cruz M, Ericzon B-G, Ikeda S-I, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31.

Syncope (transient loss of consciousness caused by global cerebral hypoperfusion) in the presence of heart disease confers risk of fatal events.33 Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-948. The Val142Ile mutation has heart failure with preserved ejection fraction (HFpEF) as the predominant clinical phenotype, with syncope being an uncommon symptom.44 Elliott P. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-77.,55 Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(2):161-72.

Case Report

The patient was male, 64 years old, of white ethnicity, engineer, born in Rio de Janeiro. He reported an isolated episode of syncope when he quickly got up from a sitting position after running. There was a history of sudden death in the family (uncle at 60). He used to take escitalopram 10 mg/day and finasteride 5 mg/day.

At physical examination: BMI of 21.8 kg/m2 and jugular turgency at 45º. BP: 140x80 mmHg, HR: 85 bpm, RR: 18 breaths per minute, fourth heart sound, sustained and palpable apex beat in the 6º intercostal space at the hemiclavicular line, clear lungs and ankle edema. He was in NYHA FC I. Blood: BNP: 233 pg/mL (NV: up to 100 pg/mL) and ultra-sensitive Troponin: 0.135 ng/mL (NV: up to 0.01 ng/mL).

The electrocardiogram (EKG) (Fig.1) showed sinus rhythm, HR: 84bpm, right bundle branch block, low voltage in frontal leads, and an pseudo-infarct pattern in precordial leads.

Figure 1
A) Electrocardiogram: Sinus rhythm, HR: 88 bpm, indeterminate QRS axis. P-wave in the frontal plane with increased duration (160 ms), with partial Bachmann’s bundle block and tricuspid P wave in D2, D3 and aVF; qR pattern in V1 and Morris index are observed in the horizontal plane, which means right and left atrial enlargement. Pseudo-infarct pattern in precordial leads and presence of low voltage in the frontal plane are also observed. B and C) Resting Cardiac MRI shows diffuse LVH, with areas of diffuse subendocardial late enhancement in the LV (arrows), atria, and interatrial septum. D and E) 99mTc-PYP myocardial scintigraphy showing intense radiotracer uptake in the myocardium (Grade 3).

The transthoracic Echocardiogram (TTE) showed left ventricular hypertrophy (LVH) - septum = 16 mm and posterior wall = 13 mm - mitral flow with type II relaxation deficit and LA indexed volume: 87 mL/m2 (Figure 2). 24-h Holter and Exercise Test (ET) showed short and asymptomatic polymorphic ventricular tachycardia (PVT) outbreaks.

Figure 2
Transthoracic echocardiogram showing pseudonormal mitral Doppler pattern (type II diastolic dysfunction), tricuspid regurgitation peak velocity >2.8 m/s and biatrial enlargement with indexed LA volume of 87 mL/m2. Parasternal longitudinal apical-4 chamber projections showing increased myocardial brightness, interatrial septum and valve thickening, and LVH. Global Longitudinal Strain showing typical amyloidosis pattern - “relative preservation of the apical regions” and longitudinal strain reduction in the basal and middle myocardial segments.

Cardiac magnetic resonance imaging (CMRI) at rest and after stress with dipyridamole requested after TTE showed diffuse LVH and absence of myocardial ischemia, with areas of lateral and anterior mesocardial late enhancement (LE) and diffuse subendocardial LE in the LV, atria and interatrial septum (Figure 1). Evaluation of global longitudinal strain (GLS) after CMRI showed marked alterations in the basal and medial portions of all myocardial walls, sparing the LV apical regions, which was consistent with the described cardiac amyloidosis (CA) pattern.

Abdominal fat and rectal biopsies confirmed the diagnosis of amyloidosis with Congo red staining. Immunofixation in blood and 24-h urine and measurement of light chains Imunoglobulins in the blood ruled out monoclonal gammopathy, after which cardiac technetium-99m pyrophosphate scintigraphy (99mTc-PYP) (Figure 1) was requested, witch showed intense radiotracer uptake in the myocardium (grade 3), suggesting Transthyretin CA (ATTR-CA) etiology.

Finally, the patient underwent genetic testing, which confirmed a heterozygous Val142Ile mutation for the TTR gene.

Discussion

When evaluating a syncope patient, it is a priority to stratify the risk of fatal events,33 Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-948. which take into account electro and echocardiographic alterations, which were present in this patient. The low voltage pattern found in the EKG (Figure 1), in the presence of LVH, are already warning signs for the diagnosis of CA.11 Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9.,44 Elliott P. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-77.,66 Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc. 2012;(2):1-13.

Elevated BNP and troponin levels reflected increased intracavitary pressures and ongoing myocardial injury, which was indicative of heart disease.

The TTE confirmed the suspected heart disease. The (Figure 2), family history of sudden death and the presence of PVT on exertion raised the suspicion of cardiac syncope and the main differential diagnoses would be hypertrophic cardiomyopathy (HCM), coronary artery disease (CAD) and CA.33 Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-948.

The CMRI, which was subsequently requested, provided evidence that was strongly suggestive of CA, given the characteristic LE pattern, ruling out the hypotheses of HCM and CAD. Because gadolinium is a purely extracellular agent and does not penetrate the intact cardiomyocyte, the characteristic appearance of LE (Figure1) in non-coronary territory is extremely suggestive of CA and this was decisive in this case.11 Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9.,44 Elliott P. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-77.,77 Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466-77.

The evaluation of myocardial deformity by the GLS technique, performed after the CMRI, demonstrated a typical pattern of CA (Figure 2), which ruled out other causes of LVH and corroborated the diagnosis, which has been very useful in this scenario.88 Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas JD, et al. Application of a Parametric Display of Two-Dimensional Speckle-Tracking Longitudinal Strain to Improve the Etiologic Diagnosis of Mild to Moderate Left Ventricular Hypertrophy. J Am Soc Echocardiogr. 2014; 27(8):888-95.

Among the CA types, the one caused by light chains Imunoglobulins (AL) is the one that most commonly affects the heart; therefore, we began with the search for hematological disease.11 Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9.,44 Elliott P. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-77.,66 Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc. 2012;(2):1-13. Since the definitive diagnosis of CA required tissue biopsy at that time, this was performed. More recent diagnostic algorithms reserve tissue biopsy only for suspected cases of AL, as the 99m-Tc-PYP myocardial scintigraphy replaced myocardial biopsy in ATTR-CA.11 Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9.,99 Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12.

This technique has been used for a long time to diagnose bone diseases, of which radiotracer has a strong affinity for calcium, that is almost only present in ATTR deposits. Positive and negative predictive values for ATTR diagnosis by 99mTc-PYP myocardial scintigraphy with a score ≥ 2 are 88 and 100%, respectively. Diagnostic certainty is proposed when the score is ≥ 2 in the absence of an immunoglobulin monoclonal peak, which would be equivalent to a positive endomyocardial biopsy,99 Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12. as in the case described (Figure1), witch was confirmed latter by the genetic testing.

The most frequent cardiac symptoms in Val142Ile ATTR are: heart failure, dyspnea, arrhythmias and dizziness. Syncope, most frequently found in AL (20%), is unusual in ATTR (8%), and when it occurs on exertion it represents the inability to increase cardiac output, which confers high mortality.55 Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(2):161-72.,1010 Marin-Acevedo JA, Sanchez-Alvarez C, Alsaad AA, Pagán RJ. Case Report Recurrent syncope, a clue in amyloid cardiomyopathy. Case Rep Med. 2018 Jan 28:1-6. Moreover, sensitivity to intravascular fluid depletion combined with autonomic neuropathy, depressed myocardial reserve, atrial dysfunction and stiffness, and the presence of arrhythmias contribute to the occurrence of syncope.66 Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc. 2012;(2):1-13. All these possibilities make syncope a multifactorial presentation in CA, as it may have occurred in the case described herein.

THAOS, an open worldwid registry to all patients with ATTR, shows that the Val142Ile, also known as Val122Ile mutation, is the second most common genotype worldwide and the most common in the USA, accounting for 23% of the total mutations in the country and 1% in the rest of the world. The carriers of this mutation are mostly of African descent and males, being prevalent in 3 to 4% of African-Americans at birth, with a penetrance of approximately 20%.55 Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(2):161-72.

ATTR is an underdiagnosed cause of HFpEF, although TTR deposits are identified in up to 30% of elderly patients referred for autopsy.11 Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9.,22 Ando Y, Coelho T, Berk JL, Waddington Cruz M, Ericzon B-G, Ikeda S-I, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31.,55 Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(2):161-72. Syncope, although uncommon in the presentation of this phenotype, may be the first symptom of this disease.

  • Sources of Funding
    There were no external funding sources for this study.
  • Study Association
    This study is not associated with any thesis or dissertation work.
  • Ethics approval and consent to participate
    This article does not contain any studies with human participants or animals performed by any of the authors.

References

  • 1
    Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Curr Opin Cardiol. 2018;33(5):571-9.
  • 2
    Ando Y, Coelho T, Berk JL, Waddington Cruz M, Ericzon B-G, Ikeda S-I, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013 Feb 20;8:31.
  • 3
    Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-948.
  • 4
    Elliott P. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-77.
  • 5
    Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2016;68(2):161-72.
  • 6
    Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc. 2012;(2):1-13.
  • 7
    Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol. 2017;70(4):466-77.
  • 8
    Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas JD, et al. Application of a Parametric Display of Two-Dimensional Speckle-Tracking Longitudinal Strain to Improve the Etiologic Diagnosis of Mild to Moderate Left Ventricular Hypertrophy. J Am Soc Echocardiogr. 2014; 27(8):888-95.
  • 9
    Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-12.
  • 10
    Marin-Acevedo JA, Sanchez-Alvarez C, Alsaad AA, Pagán RJ. Case Report Recurrent syncope, a clue in amyloid cardiomyopathy. Case Rep Med. 2018 Jan 28:1-6.

Publication Dates

  • Publication in this collection
    14 Nov 2019
  • Date of issue
    Apr 2020

History

  • Received
    03 Aug 2018
  • Reviewed
    11 Dec 2018
  • Accepted
    19 Dec 2018
Sociedade Brasileira de Cardiologia - SBC Avenida Marechal Câmara, 160, sala: 330, Centro, CEP: 20020-907, (21) 3478-2700 - Rio de Janeiro - RJ - Brazil, Fax: +55 21 3478-2770 - São Paulo - SP - Brazil
E-mail: revista@cardiol.br